BioCentury
ARTICLE | Company News

Leo Pharma, Virobay deal

January 16, 2012 8:00 AM UTC

Virobay granted LEO exclusive, worldwide rights to develop an undisclosed oral cathepsin inhibitor. The product is in preclinical testing to treat psoriasis, with Phase I testing expected to start in ...